Immunogenicity and Safety of 9vHPV Vaccine in Chinese Females 9 to 45 Years of Age

Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co. Primary endpoints: Competitive Luminex Immunoassay Geometric Mean Titers for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 60, Percentage of Participants Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 60 and 2 more. Started Apr 2019; status: completed.